Effect of Zolpidem on Clinical Efficacy, Prognosis and Safety in Patients with Variant Angina Pectoris and Self-reported Insomnia

OBJECTIVE To explore the effect of zolpidem on the clinical efficacy, prognosis and safety of patients with variant angina pectoris(VAP) and self-reported insomnia(SRI). METHODS Ninety-eight patients with VAP and SRI were randomly divided into the control group(conventional treatment and placebo) and experimental group(conventional treatment with zolpidem), 49 patients in each group. The experimental group was given zolpidem 5-10 mg orally before bedtime on the basis of routine treatment of VAP. The control group was given the same type of placebo. After treatment for 30 d, the Pittsburgh sleep quality index(PSQI) scores and SF-36 life quality scores were compared, the tumor necrosis factor a(TNF-a), interleukin 10(IL-10), and lipoprotein associated phospholipase A2(Lp-PLA₂) levels were observed, the frequency and duration of VAP and nitroglycerin consumption between two groups before and after treatment were compared, and the occurrence of cardiovascular events and adverse reactions during treatment were also evaluated. RESULTS After treatment for 30 d, the PSQI scores and SF-36 scores were improved in both groups(P<0.05) while the experimental group showed better than the control group(P<0.05). The levels of TNF-α and Lp-PLA₂ were decreased in both groups(P<0.05) and the levels of IL-10 were increased(P<0.05), and the experimental group showed more changes than the control group(P<0.05). Meanwhile, cardiovascular events were reduced in both groups, and more significant in the experimental group(P<0.05). The total incidence of drug adverse reactions in the control group and the experimental group were 6.12% and 8.16%, respectively, with no statistical difference between two groups(P>0.05). CONCLUSION Zolpidem can significantly improve the sleep and life quality of patients with VAP and SRI, reduce their vascular inflammation, and improve the treatment effect of VAP and the incidence of cardiovascular events, without increasing the overall incidence of adverse reactions.